Coombs Test - Direct, in Visit Clinic

The direct Coombs test (direct antiglobulin test) detects antibodies or complement already bound to a patient’s red blood cells. It is a laboratory test performed on a blood sample. It’s used to diagnose immune‑mediated hemolysis such as autoimmune hemolytic anemia, hemolytic transfusion reactions, hemolytic disease of the newborn and some drug‑induced hemolysis. A positive result supports immune‑driven RBC destruction and guides evaluation and treatment.

A positive Coombs test means antibodies or complement are attached to red blood cells, indicating an immune process against RBCs. This suggests immune-mediated hemolysis — causes include autoimmune hemolytic anemia, transfusion reactions, hemolytic disease of the newborn, or drug-induced hemolysis. A positive direct Coombs detects bound antibodies on a patient’s red cells; a positive indirect Coombs shows free antibodies in serum.

The direct Coombs test detects antibodies or complement already bound to a patient’s red blood cells (in vivo), used to diagnose autoimmune hemolytic anemia, transfusion reactions, and hemolytic disease of the newborn. The indirect Coombs test detects free anti‑red‑cell antibodies in a patient’s serum (in vitro), used for antibody screening in blood typing, prenatal testing, and pre‑transfusion compatibility.

If a direct antiglobulin (DCT) test is positive, contact your clinician promptly. They’ll assess for hemolysis with CBC, reticulocyte count, bilirubin, LDH and peripheral smear, review medications and transfusion history, and test for autoimmune or drug-induced causes. Treatment may include stopping offending drugs, steroids or other immunosuppressants, transfusion if needed, and referral to a hematologist with close monitoring of hemoglobin, jaundice and renal function.

The Coombs test detects antibodies or complement on red blood cells, helping diagnose immune (autoimmune or alloimmune) hemolytic anemia and hemolytic disease of the newborn. It guides transfusion compatibility, identifies drug‑induced hemolysis, monitors autoimmune hemolysis activity, and informs treatment decisions to prevent transfusion reactions and manage neonatal or adult hemolytic conditions.

The normal result for both the direct (DAT) and indirect Coombs tests is negative, meaning no agglutination and no detectable bound or free anti‑red‑cell antibodies. Some labs report a graded positive (1+ to 4+) when antibodies/complement are present; any positive result is abnormal and requires clinical correlation. Interpretation depends on test type, sample handling and patient context.